Tumor Markers for Breast Cancer: Current Utilities and Future Prospects

Hayes, Daniel F.

doi:10.1016/s0889-8588(18)30165-5

Cited by 12 publications

(6 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Disease progression can therefore be accompanied by increased presence of large glycoproteins in the serum [16]. CA15-3 has been shown to be an independent predictor of first recurrence in multivariate analyses, and a powerful prognostic indicator in patients with advanced breast cancer [17], but its role in monitoring patients with no overt disease has not been established [18][19][20].…”

mentioning

confidence: 99%

CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials

et al. 2007

View full text Add to dashboard Cite

Background: We evaluated the ability of CA15-3 and alkaline phosphatase (ALP) to predict breast cancer recurrence.Patients and methods: Data from seven International Breast Cancer Study Group trials were combined. The primary end point was relapse-free survival (RFS) (time from randomization to first breast cancer recurrence), and analyses included 3953 patients with one or more CA15-3 and ALP measurement during their RFS period. CA15-3 was considered abnormal if >30 U/ml or >50% higher than the first value recorded; ALP was recorded as normal, abnormal, or equivocal. Cox proportional hazards models with a time-varying indicator for abnormal CA15-3 and/or ALP were utilized.Results: Overall, 784 patients (20%) had a recurrence, before which 274 (35%) had one or more abnormal CA15-3 and 35 (4%) had one or more abnormal ALP. Risk of recurrence increased by 30% for patients with abnormal CA15-3 [hazard ratio (HR) = 1.30; P = 0.0005], and by 4% for those with abnormal ALP (HR = 1.04; P = 0.82). Recurrence risk was greatest for patients with either (HR = 2.40; P < 0.0001) and with both (HR = 4.69; P < 0.0001) biomarkers abnormal. ALP better predicted liver recurrence.Conclusions: CA15-3 was better able to predict breast cancer recurrence than ALP, but use of both biomarkers together provided a better early indicator of recurrence. Whether routine use of these biomarkers improves overall survival remains an open question.

show abstract

mentioning

confidence: 99%

CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The presence of pMQ1 in breast and astrocytoma cancer cells suggests that it is a tumour‐associated protein. Other tumour‐associated markers have found clinical application in the diagnosis, detection and monitoring of cancer progression28–31. In a practical setting, pMQ1 may have potential as an additional tool for the histological diagnosis and detection of minimal residual disease in women with breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of glycoprotein pMQ1 in breast cancer

Fon

Lioe

Mulligan

et al. 2006

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…Accurate, reproducible, and readily detectable prognostic factors are necessary to appropriately risk-stratify patients [7][8][9]. Prognostic markers are defined as those factors that predict outcome in the absence of systemic therapy.…”

Section: Conventional Prognostic and Predictive Factorsmentioning

confidence: 99%